Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olutasidenib + cytarabine
- Development stage
- Phase 2
- Lead developer
- Rigel Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Olutasidenib + cytarabine is an investigational combination treatment composed of olutasidenib, a potent and selective small molecule inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), combined with cytarabine, a nucleoside analog antimetabolite chemotherapy. Olutasidenib targets and inhibits the neomorphic enzymatic activity of mutant IDH1, thereby reducing the production of the oncometabolite 2-hydroxyglutarate, which contributes to leukemogenesis. Cytarabine incorporates into DNA during replication, inhibiting DNA synthesis and inducing apoptosis in rapidly proliferating cells. The combination has been studied in patients with relapsed or refractory acute myeloid leukemia (AML) harboring an IDH1 mutation, including within a multi-arm phase 1/2 clinical trial. The purpose of the combination is to assess synergistic or additive efficacy in high-risk or refractory AML populations. Both agents are administered via established dosing regimens within clinical trials, but the combination is not yet approved for standard care.
- Brand names
- Rezlidhia + cytarabine
- Other names
- olutasidenib hydrochloride + cytarabine
02
Targets
IDH1 (Isocitrate dehydrogenase [NADP] cytoplasmic)
Beyond the preview
Go deeper on olutasidenib + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olutasidenib + cytarabine.